Sookoian Silvia, Pirola Carlos J
School of Medicine, Institute of Medical Research A Lanari, University of Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
Department of Clinical and Molecular Hepatology, Institute of Medical Research (IDIM), National Scientific and Technical Research Council (CONICET), University of Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
Hepatobiliary Surg Nutr. 2021 Jun;10(3):337-349. doi: 10.21037/hbsn-20-270.
Nonalcoholic fatty liver disease (NAFLD) pathogenesis is explained by the complex relationship among diet and lifestyle-predisposing factors, the genetic variance of the nuclear and mitochondrial genome, associated phenotypic traits, and the yet not fully explored interactions with epigenetic and other environmental factors, including the microbiome. Despite the wealth of knowledge gained from molecular and genome-wide investigations in patients with NAFLD, the precise mechanisms that explain the variability of the histological phenotypes are not fully understood. Earlier studies of the gut microbiota in patients with NAFLD and nonalcoholic steatohepatitis (NASH) provided clues on the role of the fecal microbiome in the disease pathogenesis. Nevertheless, the composition of the gut microbiota does not fully explain tissue-specific mechanisms associated with the degree of disease severity, including liver inflammation, ballooning of hepatocytes, and fibrosis. The liver acts as a key filtration system of the whole body by receiving blood from the hepatic artery and the portal vein. Therefore, not only microbes would become entrapped in the complex liver anatomy but, more importantly, bacterial derived products that are likely to be potentially powerful stimuli for initiating the inflammatory response. Hence, the study of liver tissue microbiota offers the opportunity of changing the paradigm of host-NAFLD-microbial interactions from a "gut-centric" to a "liver-centric" approach. Here, we highlight the evidence on the role of liver tissue bacterial DNA in the biology of NAFLD and NASH. Besides, we provide evidence of metagenomic findings that can serve as the seed of further hypothesis-raising studies as well as can be leveraged to discover novel therapeutic targets.
非酒精性脂肪性肝病(NAFLD)的发病机制可通过饮食与生活方式诱发因素、核基因组和线粒体基因组的基因变异、相关表型特征以及与表观遗传和其他环境因素(包括微生物群)之间尚未完全探索的相互作用之间的复杂关系来解释。尽管从对NAFLD患者的分子和全基因组研究中获得了丰富的知识,但解释组织学表型变异性的精确机制仍未完全明了。早期对NAFLD和非酒精性脂肪性肝炎(NASH)患者肠道微生物群的研究为粪便微生物群在疾病发病机制中的作用提供了线索。然而,肠道微生物群的组成并不能完全解释与疾病严重程度相关的组织特异性机制,包括肝脏炎症、肝细胞气球样变和纤维化。肝脏通过接收来自肝动脉和门静脉的血液,作为全身的关键过滤系统。因此,不仅微生物会被困在复杂的肝脏解剖结构中,更重要的是,细菌衍生产物可能是引发炎症反应的潜在强大刺激物。因此,对肝脏组织微生物群的研究为将宿主-NAFLD-微生物相互作用的范式从“以肠道为中心”转变为“以肝脏为中心”的方法提供了机会。在此,我们强调肝脏组织细菌DNA在NAFLD和NASH生物学中作用的证据。此外,我们提供了宏基因组学研究结果的证据,这些结果可作为进一步提出假设研究的起点,并可用于发现新的治疗靶点。